Maxim Group Lowers Tenon Medical (NASDAQ:TNON) Price Target to $8.00

Tenon Medical (NASDAQ:TNON) had its price objective dropped by equities researchers at Maxim Group from $22.00 to $8.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 195.20% from the stock’s current price.

Separately, Benchmark reissued a “speculative buy” rating and issued a $3.00 target price on shares of Tenon Medical in a report on Wednesday, August 14th.

Tenon Medical Price Performance

Shares of TNON stock opened at $2.71 on Friday. The stock has a 50 day simple moving average of $4.05 and a 200-day simple moving average of $1.87. Tenon Medical has a 12-month low of $2.61 and a 12-month high of $22.32.

Tenon Medical Company Profile

Tenon Medical, Inc, a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints.